Seropositive rheumatoid arthritis N = 4998 | Seronegative rheumatoid arthritis N = 2340 | Undifferentiated arthritis N = 2433 | p-value | |
---|---|---|---|---|
Females N (%) | 3349 (67.0) | 1584 (67.7) | 1650 (67.8) | |
Mean age at diagnosis, years (SD) | 58 (15) | 56 (17) | 49 (17) | |
Number of DMARD purchases, median (IQR) | 11 (7, 16) | 10 (6, 14) | 7 (4, 11) | < 0.001 |
Medications | ||||
Methotrexate (MTX) | 4167 (83.4) | 1789 (76.4) | 1512 (62.1) | < 0.001 |
MTX per os | 3998 (80.0) | 1706 (72.9) | 1406 (57.8) | |
MTX s.c. | 625 (12.5) | 308 (13.2) | 310 (12.7) | |
Sulfasalazine (SSZ) | 2520 (50.4) | 1090 (46.6) | 1362 (56.0) | < 0.001 |
Hydroxychloroquine (HCQ) | 3603 (72.1) | 1357 (58.0) | 866 (35.6) | < 0.001 |
Leflunomide | 256 (5.1) | 121 (5.2) | 119 (4.9) | 0.89 |
Azathioprine | 65 (1.3) | 31 (1.3) | 23 (0.9) | 0.37 |
Aurathiomalate | 42 (0.8) | 12 (0.5) | 8 (0.3) | 0.023 |
Auranofin | 4 (0.1) | 2 (0.1) | 2 (0.1) | 0.99 |
Cyclosporine | 13 (0.3) | 10 (0.4) | 23 (0.9) | < 0.001 |
Prednisolone (PRD) | 3626 (72.6) | 1706 (72.9) | 1283 (52.7) | < 0.001 |
Self-injected biologics (all) | 131 (2.6) | 125 (5.3) | 76 (3.1) | < 0.001 |
Etanercept | 53 (1.1) | 55 (2.4) | 31 (1.3) | |
Adalimumab | 40 (0.8) | 48 (2.1) | 29 (1.2) | |
Certolizumab | 23 0.5) | 19 (0.8) | 12 (0.5) | |
Golimumab | 19 (0.4) | 19 (0.8) | 9 (0.4) | |
Abatacept | 8 (0.2) | 5 (0.2) | 1 (0.04) | |
Tocilizumab | 4 (0.1) | 1 (0.04) | 1 (0.04) | |
Ustekinumab | 0 (0) | 0 (0) | 1 (0.04) | |
No antirheumatic medication | 71 (1.4) | 60 (2.6) | 73 (3.0) | < 0.001 |
Only prednisolone | 25 (0.5) | 30 (1.3) | 24 (1.0) | < 0.001 |